JPS58164512A - プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤 - Google Patents

プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤

Info

Publication number
JPS58164512A
JPS58164512A JP57046380A JP4638082A JPS58164512A JP S58164512 A JPS58164512 A JP S58164512A JP 57046380 A JP57046380 A JP 57046380A JP 4638082 A JP4638082 A JP 4638082A JP S58164512 A JPS58164512 A JP S58164512A
Authority
JP
Japan
Prior art keywords
therapeutic agent
cell
disorder
active ingredient
methyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57046380A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0227970B2 (enExample
Inventor
Yoshinori Sakai
芳紀 酒井
Katsuhiro Imaki
今木　勝広
Takashi Muryorin
無量林　尭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to JP57046380A priority Critical patent/JPS58164512A/ja
Priority to DE3310556A priority patent/DE3310556A1/de
Priority to US06/478,031 priority patent/US4464388A/en
Priority to BE0/210404A priority patent/BE896274A/fr
Publication of JPS58164512A publication Critical patent/JPS58164512A/ja
Publication of JPH0227970B2 publication Critical patent/JPH0227970B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP57046380A 1982-03-25 1982-03-25 プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤 Granted JPS58164512A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP57046380A JPS58164512A (ja) 1982-03-25 1982-03-25 プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤
DE3310556A DE3310556A1 (de) 1982-03-25 1983-03-23 Verwendung von prostaglandinanalogen
US06/478,031 US4464388A (en) 1982-03-25 1983-03-23 Use of prostaglandin analogues to treat cytodamage
BE0/210404A BE896274A (fr) 1982-03-25 1983-03-25 Nouvelle utilisation d'analogues de prostaglandines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57046380A JPS58164512A (ja) 1982-03-25 1982-03-25 プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP29170289A Division JPH02160721A (ja) 1989-11-09 1989-11-09 プロスタグランジン類似化合物を有効成分として含有する膵炎治療剤

Publications (2)

Publication Number Publication Date
JPS58164512A true JPS58164512A (ja) 1983-09-29
JPH0227970B2 JPH0227970B2 (enExample) 1990-06-20

Family

ID=12745531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57046380A Granted JPS58164512A (ja) 1982-03-25 1982-03-25 プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤

Country Status (4)

Country Link
US (1) US4464388A (enExample)
JP (1) JPS58164512A (enExample)
BE (1) BE896274A (enExample)
DE (1) DE3310556A1 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130554A (ja) * 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
EP0430552A2 (en) 1989-11-22 1991-06-05 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
JPH0649649B2 (ja) * 1984-07-25 1994-06-29 シエ−リング アクチエンゲゼルシヤフト 腎臓障害の阻止治療薬
EP0690049A2 (en) 1994-06-03 1996-01-03 R-Tech Ueno Ltd. Agent for treating hepato biliary diseases
WO1998040073A1 (fr) * 1997-03-13 1998-09-17 Toray Industries, Inc. Medicament pour traiter les lesions vasculaires diabetiques
WO1998041209A1 (fr) * 1997-03-14 1998-09-24 Toray Industries, Inc. Agents protecteurs de la cellule nerveuse
JP2013543491A (ja) * 2010-10-01 2013-12-05 リグスホスピタル 急性外傷性凝固障害及び蘇生した心停止の予防または処置に使用するための血管内皮の完全性を調節または保存できる化合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59163365A (ja) * 1983-03-08 1984-09-14 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
US5380667A (en) * 1992-10-30 1995-01-10 The United States Of America As Represented By The Secretary Of The Air Force Serum bilirubin and liver function tests as risk predictors for coronary artery disease
BR0012907A (pt) 1999-08-05 2002-06-11 Teijin Ltd Agente para o remédio de dano neural, composto contendo nitrogênio, e, composição farmacêutica
DE10160935A1 (de) * 2001-12-12 2003-07-17 Daimler Chrysler Ag Kraftfahrzeugkühlvorrichtung für elektronische Geräte

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081553A (en) * 1976-02-17 1978-03-28 The Upjohn Company Cytoprotective prostaglandins for use in human intestinal diseases
US4083998A (en) * 1976-02-17 1978-04-11 The Upjohn Company Treatment of inflammatory diseases of the mammalian large intestine with cytoprotective prostaglandins
US4097603A (en) * 1977-09-06 1978-06-27 The Upjohn Company Gastric cytoprotection with non-antisecretory doses of prostaglandins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5395958A (en) * 1977-01-31 1978-08-22 Ono Pharmaceut Co Ltd Prostaglandin analogues and process for their preparation
US4178367A (en) * 1977-02-21 1979-12-11 Ono Pharmaceutical Co. Ltd. Prostaglandin I2 analogues
JPS6022710B2 (ja) * 1977-09-16 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
JPS5452069A (en) * 1977-09-29 1979-04-24 Ono Pharmaceut Co Ltd Prostaglandin i2 analog compound and its preparation
JPS54125653A (en) * 1978-03-18 1979-09-29 Ono Pharmaceut Co Ltd Prostaglandin i2 analog, its preparation, and drug composition comprising it as active constituent
DE2947526A1 (de) * 1978-11-29 1980-06-12 Ono Pharmaceutical Co Prostacyclin-analoge

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081553A (en) * 1976-02-17 1978-03-28 The Upjohn Company Cytoprotective prostaglandins for use in human intestinal diseases
US4083998A (en) * 1976-02-17 1978-04-11 The Upjohn Company Treatment of inflammatory diseases of the mammalian large intestine with cytoprotective prostaglandins
US4097603A (en) * 1977-09-06 1978-06-27 The Upjohn Company Gastric cytoprotection with non-antisecretory doses of prostaglandins

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130554A (ja) * 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
JPH0649649B2 (ja) * 1984-07-25 1994-06-29 シエ−リング アクチエンゲゼルシヤフト 腎臓障害の阻止治療薬
EP0430552A2 (en) 1989-11-22 1991-06-05 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
EP0690049A2 (en) 1994-06-03 1996-01-03 R-Tech Ueno Ltd. Agent for treating hepato biliary diseases
WO1998040073A1 (fr) * 1997-03-13 1998-09-17 Toray Industries, Inc. Medicament pour traiter les lesions vasculaires diabetiques
WO1998041209A1 (fr) * 1997-03-14 1998-09-24 Toray Industries, Inc. Agents protecteurs de la cellule nerveuse
JP2013543491A (ja) * 2010-10-01 2013-12-05 リグスホスピタル 急性外傷性凝固障害及び蘇生した心停止の予防または処置に使用するための血管内皮の完全性を調節または保存できる化合物

Also Published As

Publication number Publication date
DE3310556C2 (enExample) 1991-07-11
US4464388A (en) 1984-08-07
DE3310556A1 (de) 1983-11-24
BE896274A (fr) 1983-09-26
JPH0227970B2 (enExample) 1990-06-20

Similar Documents

Publication Publication Date Title
DE3850676T2 (de) Hypotensive okulare Mittel.
DE3608088C2 (de) Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
JPS58164512A (ja) プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤
US4054736A (en) Clathrate compounds of prostaglandins or their analogues with cyclodextrin
JPH0314286B2 (enExample)
DE68918391T2 (de) Okulare hypotensive Mittel.
JP2650756B2 (ja) 皮膚および粘膜上皮の疾患の治療のための４‐キノリンカルボン酸誘導体
JPH0380772B2 (enExample)
JPS58203911A (ja) プロスタグランジン類似化合物を有効成分として含有する細肪障害治療剤
AT396687B (de) Cyclodextrinclathrate von 5-cyanoprostacyclinderivaten und ihre verwendung als arzneimittel
CH638510A5 (de) Prostacyclinanaloga.
JPH05503713A (ja) ９―ハロゲン―１１β―ヒドロキシ―プロスタグランジン誘導体、その製造法および医薬品としてのその使用
JPS6144819A (ja) プロスタグランジンｉ２類縁化合物を含有する循環改善作用を有する薬剤
JPH06505259A (ja) 複素環式化合物
JPH0120A (ja) 臓器保護剤
CN110724147A (zh) 一种替格瑞洛衍生物及其制备方法和应用
US3717649A (en) 2-diethylamino-ethyl nicotinate, para-chloro-phenoxy-isobutyric acid salt
CA2138297A1 (en) Novel pharmaceutical use of dihydropyridine derivative
JPH07100656B2 (ja) 白内障処置剤
HU190722B (en) Process for producing new carbacycline esters and pharmaceutical compositions containing them
JPH05221901A (ja) セコステロール誘導体
JPS61243073A (ja) ７−オキソ−プロスタサイクリン誘導体、その製法および医薬組成物
JP2760514B2 (ja) 循環機能昂進剤
JPH024590B2 (enExample)
JPH0480006B2 (enExample)